Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Maxcyte Inc
(NQ:
MXCT
)
3.710
+0.020 (+0.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
340,219
Open
3.670
Bid (Size)
3.630 (2)
Ask (Size)
3.760 (20)
Prev. Close
3.690
Today's Range
3.585 - 3.740
52wk Range
2.450 - 5.545
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
April 10, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
April 02, 2024
Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs
From
MaxCyte, Inc
Via
GlobeNewswire
Performance
YTD
-25.80%
-25.80%
1 Month
-11.46%
-11.46%
3 Month
-27.96%
-27.96%
6 Month
+25.34%
+25.34%
1 Year
-25.80%
-25.80%
More News
Read More
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
March 20, 2024
Via
Benzinga
MaxCyte Earnings Preview
March 11, 2024
Via
Benzinga
Recap: MaxCyte Q3 Earnings
November 08, 2023
Via
Benzinga
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
March 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
March 13, 2024
Via
Benzinga
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
March 13, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
March 12, 2024
Via
Benzinga
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
March 12, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Earnings Scheduled For March 12, 2024
March 12, 2024
Via
Benzinga
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
March 04, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
February 09, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
January 30, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
January 23, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
January 09, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Cell Engineering Company MaxCyte Shares Are Up Today
January 09, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
January 08, 2024
Via
Benzinga
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
January 08, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
January 03, 2024
From
MaxCyte, Inc; Lion TCR
Via
GlobeNewswire
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
January 02, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
December 11, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 06, 2023
Via
Benzinga
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
November 16, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
November 08, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.